



# iCo Therapeutics

iCo Therapeutics Inc. is a Vancouver-based reprofiling company focused on redosing or reformulating drugs with clinical history for new or expanded indications. iCo has exclusive worldwide rights to three products: iCo-007, in Phase 2 for the treatment of Diabetic Macular Edema (DME), iCo-008 (Bertilimumab), a product with Phase 2 clinical history to be developed for sight-threatening diseases; and an oral Amphotericin B delivery system for life-threatening infectious diseases. Immune Pharmaceuticals licensed systemic rights to iCo-008 in June 2011. iCo trades on the TSX Venture Exchange under the symbol "ICO".

## BUSINESS MODEL

Risk-mitigated model

- Acquire promising drug candidates with identified targets and demonstration of systemic safety
- Develop novel reformulations
- Expand and create new indications for drugs

Focused on underserved markets

Efficient use of capital

Experienced management & board

## INVESTMENT HIGHLIGHTS

Broad product pipeline

Worldwide exclusive rights to all indications

Large market opportunities

Compelling clinical & preclinical data

## RECENT & UPCOMING MILESTONES

### iCo-007 for Diabetes Related Blindness

- ✓ Completed "fill finish" manufacturing to produce clinical supply
  - ✓ US FDA Clearance for Phase 2
  - ✓ US Phase 2 trial initiated August 2011
  - ✓ US Phase 2 Research Collaboration with JDRF
- Interim results H2 2012  
Ongoing regional partnership discussions

### iCo-008 for Sight-Threatening Disease

- ✓ Licensed systemic rights to Immune Pharmaceuticals US\$32 + Million while retaining ocular rights
- Pursuing non-dilutive funding of ocular programs

### Oral Amphotericin B Delivery System

- Phase 1 trial planned for 2012  
Pursuing non-dilutive funding

## Advancing New Treatments for Ophthalmic Diseases

### FINANCIAL DATA

Symbol TSX-V "ICO"

Invested Capital to Date: \$19.9M

Year Range \$0.20- \$0.42

### Shares Outstanding

Basic: 46.6M

Fully Diluted: 54.7M

### Shareholders

ISIS Pharmaceuticals: 11%

Special Situations: 13%

Management 10%

### Equity Analyst Coverage

Douglas Loe, Byron Capital Markets

## MANAGEMENT

### Andrew Rae, MBA

Co-founder, Director,  
President & CEO

### John Meekison, BA, CIM, P. Log.

Co-founder & CFO

### Peter Hnik, MD, MHSc.

Chief Medical Officer

760-777 Hornby St  
Vancouver, BC Canada V6Z 1S4  
604-602-9414  
[www.icotherapeutics.com](http://www.icotherapeutics.com)